Research
Hormonal
Liraglutide and semaglutide are the only approved anti-obesity medications demonstrated to lower the risk of major cardiovascular events in patients with or without established cardiovascular disease.
For patients with obesity and existing heart disease or diabetes, Liraglutide (3mg daily) and Semaglutide (2.4mg weekly) are preferred because they reduce cardiovascular event risk, unlike other weight loss drugs.
StrongSupportsHIGH confidence
Although all anti-obesity medications have been demonstrated to improve cardiometabolic risk factors, only liraglutide and semaglutide lower the risk of major cardiovascular events in patients with or without established cardiovascular disease.
Why this rating
Cited as a primary advantage with specific trial references.
Source
Pharmacotherapy of obesity: State of the art and perspectives
Katarina Sićović et al. · Arhiv za farmaciju · 2024
DOI 10.5937/arhfarm74-50625
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (semaglutide, tirzepatide) produce superior weight loss (>10% initial body weight) compared to other approved anti-obesity medications by acting centrally to increase satiety and reduce appetite.Strong
- Non-pharmacological lifestyle interventions (caloric deficit >500 kcal/day, physical activity >200 min/week) can achieve up to 8% mean weight loss over 6 months, comparable to moderate-efficacy anti-obesity medications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →